Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026
Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026
Same author

New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.

Blood cancer discovery·2026
Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026
Same author

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.

American journal of hematology·2026
Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Extramedullary multiple myeloma.

Matthew Weinstock1, Irene M Ghobrial

  • 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.

Leukemia & Lymphoma
|December 6, 2012
PubMed
Summary
This summary is machine-generated.

Extramedullary disease (EMD) is a manifestation of multiple myeloma found outside the bone marrow. Research is needed to understand its aggressive nature and distinct features.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: May 16, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Hematology
  • Oncology

Background:

  • Extramedullary disease (EMD) involves clonal plasmacytic infiltration outside the bone marrow in multiple myeloma patients.
  • EMD prevalence varies, cited between 6% and 20% in different studies.
  • EMD is considered an uncommon yet significant manifestation of multiple myeloma.

Purpose of the Study:

  • To summarize current research on extramedullary disease (EMD) in multiple myeloma.
  • To highlight the need for further investigation into EMD's characteristics.
  • To explore the pathogenic, immunologic, cytogenetic, clinical, therapeutic, and prognostic aspects of EMD.

Main Methods:

  • Review of existing observational series and literature on extramedullary disease.
  • Synthesis of data regarding the prevalence and clinical behavior of EMD.
  • Identification of research gaps and future research opportunities.

Main Results:

  • Extramedullary disease (EMD) is a recognized complication of multiple myeloma.
  • Observational data suggests EMD exhibits aggressive behavior distinct from marrow-restricted myeloma.
  • The precise prevalence and comprehensive understanding of EMD remain incompletely described.

Conclusions:

  • Extramedullary disease (EMD) represents a distinct and aggressive subtype of multiple myeloma.
  • Further research is crucial to elucidate the multifaceted features of EMD.
  • Understanding EMD is essential for improving patient outcomes in multiple myeloma.